A user is seeking a UK source for a combined minoxidil and RU58841 solution that doesn't contain scalp-irritating ingredients. They specifically want a product without propylene glycol (PG).
The conversation discusses alternatives to RU58841 for hair loss treatment, with suggestions including topical spironolactone, peppermint and rosemary oils, and saw palmetto. The user also considers ordering RU58841 from China but finds it too expensive.
The conversation discusses making a RU58841 solution for hair loss prevention and includes personal experiences with using RU58841 and minoxidil for hair regrowth, with a mention of monitoring health effects.
OP asked if a product from Amazon is sufficient to dilute finasteride. A user advised against using propylene glycol alone, suggesting a pre-made solution instead.
A female user is using a 5% RU58841 solution with 5 sprays daily and is concerned about potential reactions and the impact of wearing a bonnet. A male user mentioned using 1ml of the same solution daily via dropper.
A user is seeking a recipe to create a topical solution using Minoxidil tablets, rosemary, peppermint, and possibly coconut oil. They are asking for specific amounts and mixing instructions.
The user experienced initial hair density improvement with finasteride, but later felt scalp pain and a plateau in results. They added alfatradiol for scalp inflammation and divi scalp serum to their routine, and are curious if others have similar experiences.
People are interested in trying clascosterone (Breezula) for hair loss, especially those who are too young for finasteride. Some users express concerns about the cost and prescription requirements, while others discuss alternatives like RU58841.
Liposomal carriers for topical finasteride offer better targeting, reduced side effects, and less irritation compared to alcohol-based solutions, but availability and cost may limit their use. Minoxidil can dissolve in liposomal carriers, enhancing delivery and stability.
The conversation humorously discusses hair loss treatments, mentioning spironolactone and cyproterone acetate. It reflects a sense of frustration and satire about the effectiveness of these treatments.
A user discusses using a serum called Dallixa, containing minoxidil-like and bimatoprost-like compounds, for hair loss and greying. The user's dermatologist advised against finasteride and suggested the serum might improve hair pigmentation.
The post and conversation are about skepticism towards a new hair loss treatment containing 2-deoxy-D-ribose, copper peptides, and exosomes, with concerns about the legitimacy of the product and its website. The treatment's effectiveness and authenticity are questioned due to lack of testing and transparency.
The user plans to use 1% Koshine826, 0.1% Alfatradiol, Minoxidil with Tretinoin, microneedling, and Stemoxydine for hair loss treatment. They expect significant recovery with this regimen.
Clascoterone 5% shows promising hair growth results but is criticized for high cost and unclear effectiveness compared to other treatments like finasteride. Glenmark is testing a combination of Clascoterone 7.5% and Minoxidil 5% in India.
PP405 increased hair density by 20% in 31% of participants, but results are considered underwhelming. Minoxidil and finasteride are seen as more effective treatments.
Clascoterone 5% topical solution is effective and safe for long-term use in treating male pattern hair loss. Cosmo Pharma aims for EU and US approval, with a potential US release in late 2027 or early 2028.
The user is experiencing irritation from using PG with RU58841 and is seeking alternative solutions like K&B in the UK. They report redness, itchiness, and flaky skin from the current treatment.
CB-03-01 is considered a failed treatment for hair loss, with future hopes pinned on PP-405 and GT-20029, expected by 2030. Alternatives like hair transplants and SMP are discussed, while some users express frustration over the slow progress of treatments like Breezula.
OP saw positive results from 4 months of finasteride, vitamin D3, and microneedling. They plan to add rosemary and castor oil but decided against using minoxidil.
The user experienced side effects like watery semen, erection problems, and decreased libido from finasteride, which resolved after stopping it. They are considering dutasteride mesotherapy as an alternative, as advised by their dermatologist, and are concerned about potential side effects.
Redensyl, a hair loss treatment that has been claimed to be 80% more effective than minoxidil, but users have not experienced any results from using it.
The user resumed using topical finasteride after a two-week break and will update on side effects like water retention and gynecomastia in a month. They are also starting DIM and zinc.
The post discusses whether a topical serum with 0.3% finasteride, 6% minoxidil, and essential oils is as effective as a spray with the same concentrations but different ingredients for scalp absorption. The user is seeking advice on which formulation absorbs better into the scalp.
SCUBE3 is available online but poses risks like tumor promotion and high costs. Users advise against using it due to health concerns and inefficacy as a standalone treatment.
RU58841 powder is mixed with a 70% ethanol and 30% propylene glycol solution, with some users seeking PG-free alternatives. Minoxidil is also mentioned as a treatment option.
Rice water was used as a hair treatment and showed noticeable results in a week, more than finasteride used for seven months. The user plans to continue using rice water and might stop finasteride, while still using ketoconazole for dandruff.
A peptide-based hair loss treatment, PP405, reportedly increased hair density by 62% in 90 days, but these claims are unverified and met with skepticism. Users compared PP405 to Minoxidil and Finasteride, expressing doubts about its effectiveness without more evidence.
PP405 is criticized for overhyped claims and cherry-picked data, with doubts about its effectiveness compared to minoxidil and finasteride. Many users express skepticism, emphasizing the need for more comprehensive trial results.